Medullary effects of nicotine and GABA on tracheal smooth muscle tone.
Airway tone can be modulated centrally by the brain as well as by peripheral receptors. In part these changes in airway caliber seem to be secondary to changes in respiratory activity. Since structures near the ventrolateral medullary surface (VMS) can produce profound effects on respiration, it seems reasonable to believe that they might also be capable of modifying tracheal tone. In this study we examined the effects of two agents with respect to their action on tracheal tone: nicotine, a respiratory stimulant when applied to the VMS, and gamma aminobutyric acid (GABA), a respiratory depressant when similarly administered. In chloralose anesthetized, paralyzed, artificially ventilated cats, tracheal tone was assessed by measuring pressure changes in a rostral bypassed segment of the trachea, while phrenic nerve activity was examined simultaneously. Nicotine administered on the intermediate area of the VMS both before and after carotid sinus denervation increased phrenic activity and induced constriction of the rostral tracheal segment. The response to nicotine could be blocked by application of a nicotine antagonist, hexamethonium, or prior local administration of lidocaine to the VMS. Activation of GABAergic receptors by application of GABA on the intermediate area of the VMS markedly reduced respiratory activity and nearly abolished the increased tracheal tone produced by inhalation of 7% CO2 in O2. The effects of GABA were eliminated by the prior administration to the VMS of bicuculline, a GABA receptor antagonist. These results indicate that structures located on the ventral surface of the medulla which affect breathing may also play a significant role in the regulation of airway smooth muscle tone.
D000287:Administration, Topical; D000403:Airway Resistance / Q000187:drug effects*; D000818:Animals; D001640:Bicuculline / Q000031:analogs & derivatives / Q000494:pharmacology; D002245:Carbon Dioxide / Q000494:pharmacology; D002415:Cats; D005260:Female; D018756:GABA Antagonists; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology; D008012:Lidocaine / Q000494:pharmacology; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects; D009538:Nicotine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010791:Phrenic Nerve / Q000187:drug effects; D014132:Trachea / Q000187:drug effects; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D018756:GABA Antagonists; D006584:Hexamethonium Compounds; D002245:Carbon Dioxide; D018738:Hexamethonium; C017069:bicuculline methiodide; D005680:gamma-Aminobutyric Acid; D009538:Nicotine; D008012:Lidocaine; D001640:Bicuculline